TNFSF10 and central nervous system cancer: While recombinant TRAIL has never reached clinical trials for the treatment of glioblastoma, TIC10/ONC201 is being studied in patients suffering from recurrent high-grade gliomas (https://clinicaltrials.gov/ct2/show/NCT02525692?term=NCT02525692&rank=1, last accessed 02/08/2016).